Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other neoplasm 1

Conditions

Rectal Neoplasms 13Breast Neoplasms 12Colorectal Neoplasms 11Colonic Neoplasms 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia 9Carcinoma, Non-Small-Cell Lung 9Leukemia, Myeloid, Acute 8Carcinoma, Renal Cell 8Prostatic Neoplasms 7Lung Neoplasms 7Kidney Neoplasms 7Multiple Myeloma 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Gliosarcoma 6Glioblastoma 6Esophageal Neoplasms 6Congenital Abnormalities 6Stomach Neoplasms 5Melanoma 5Lymphoma, Mantle-Cell 5Lymphoma, Large-Cell, Anaplastic 5Leukemia, Lymphocytic, Chronic, B-Cell 5Central Nervous System Neoplasms 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Myelodysplastic Syndromes 4Lymphoma, Large-Cell, Immunoblastic 4

Interventions

Dexamethasone 110Cyclophosphamide 99Melphalan 91Bortezomib 68Peripheral Blood Stem Cell Transplantation 63Lenalidomide 57fludarabine phosphate 55Busulfan 53Filgrastim 50Antilymphocyte Serum 38Tacrolimus 37Thalidomide 36Radiotherapy 36Mycophenolic Acid 32fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Prednisone 21Whole-Body Irradiation 20Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 14Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Plasma Cell × Gene Expression Profiling × Clear all
NCT00942422 2015-03-27

Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

Barbara Ann Karmanos Cancer Institute

Phase 2 Terminated
8 enrolled 5 charts
Other neoplasmPlasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

NCT00482495 2011-05-11

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 2 Completed
42 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡